Valuation check: 4732.TWO's profit margin is -48.86%, below the Healthcare sector average of 17.63%.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
NatureWise Biotech & Medicals posts a profit margin of -48.86% as of June 2026. That compares with 7.3% in the prior-year period — down 769.0% year over year. That is below the Healthcare sector average of 17.63%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
In the prior comparable period, NatureWise Biotech & Medicals's profit margin was 7.3%. The latest reading is -48.86% — a 769.0% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.
For Healthcare stocks, a profit margin near 17.63% is typical. NatureWise Biotech & Medicals's -48.86% is lower that level. That is roughly 377.2% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
NatureWise Biotech & Medicals's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -48.86% as of June 2026; use YoY and peer views to separate noise from signal.
Context for 4732.TWO's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 17.63%), and (3) consistency with growth and profitability. This page covers the first two; NatureWise Biotech & Medicals's other metric pages and overview cover the third.